Patents by Inventor Louis Cannizzo

Louis Cannizzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925617
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 12, 2024
    Assignees: NORTHROP GRUMMAN SYSTEMS, CORPORATION and EPICENTRX, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20220016077
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 20, 2022
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20200046682
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 13, 2020
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 10149832
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: December 11, 2018
    Assignees: EpicentRx, Inc., Orbital ATK, Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20180085346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 29, 2018
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20160199346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Inventors: MARK D. BEDNARSKI, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 9226915
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 5, 2016
    Assignees: EPICENTRX, INC., ORBITAL ATK, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20150246020
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 29, 2014
    Publication date: September 3, 2015
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 8927527
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 6, 2015
    Assignees: EpicentRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 8664247
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: March 4, 2014
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Publication number: 20130053418
    Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 28, 2013
    Inventors: Jan Scicinski, Bryan T. Oronsky, Robert Wardle, Louis Cannizzo, Nicholas A. Straessler
  • Patent number: 8299053
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: October 30, 2012
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Applicants: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS, ALLIANT TECHSYSTEMS INC.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20090163466
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 25, 2009
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 7507842
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 24, 2009
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning, Mark D. Bednarski
  • Publication number: 20070135380
    Abstract: The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 11, 2006
    Publication date: June 14, 2007
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark Bednarski, Lynn Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20070135384
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 11, 2006
    Publication date: June 14, 2007
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning, Lynn Oehler
  • Publication number: 20060157173
    Abstract: This thermoplastic elastomer is present in a substantially solid state suitable for use as a binder for a propellant, explosive, and/or gas generant of a supplemental restraint system. The thermoplastic elastomer is formed from a composition including A blocks which are crystalline at temperatures below about 75° C. and B blocks which are amorphous at temperatures above about ?20° C. The A blocks are derived from oxetane derivatives and the B blocks are derived from oxiranes and derivatives thereof. The A blocks and B-blocks are end-capped with a diisocyanate having a first isocyanate moiety that is substantially more reactive with the terminal groups of the blocks than the second isocyanate moiety, whereby the more reactive first isocyanate moiety is capable of reacting with the terminal groups of the blocks, leaving the less reactive second isocyanate moiety free and unreacted.
    Type: Application
    Filed: February 14, 2006
    Publication date: July 20, 2006
    Inventors: Andrew Sanderson, Wayne Edwards, Louis Cannizzo, Robert Wardle
  • Patent number: 6414143
    Abstract: Nitramine oxidizers are recovered from propellant, explosive, and pyrotechnic materials with a concentrated mineral acid bath, preferably comprising 70 to 90 wt. % nitric acid, that serves to dissolve the nitramine oxidizers into solution and permit filtration of the binder therefrom. The recovery process is conducted in the absence of organic solvents.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: July 2, 2002
    Assignee: Alliant Techsystems Inc.
    Inventors: Louis Cannizzo, Lew Huntsmann